Literature DB >> 15105159

In vitro activity of anidulafungin against selected clinically important mold isolates.

Zekaver Odabasi1, Victor L Paetznick, Jose R Rodriguez, Enuo Chen, Luis Ostrosky-Zeichner.   

Abstract

In this study, we evaluated the in vitro activity of anidulafungin against selected mold isolates. Anidulafungin showed promising activity against Bipolaris spicifera, Exophiala jeanselmei, Fonsecaea pedrosoi, Madurella mycetomatis, Penicillium marneffei, Phialophora verrucosa, Pseudallescheria boydii, Sporothrix schenckii, and Wangiella dermatitidis.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15105159      PMCID： PMC400581          DOI： 10.1128/AAC.48.5.1912-1915.2004

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  31 in total

1.  In vitro activity of two echinocandin derivatives, LY303366 and MK-0991 (L-743,792), against clinical isolates of Aspergillus, Fusarium, Rhizopus, and other filamentous fungi.

Authors:  M A Pfaller; F Marco; S A Messer; R N Jones
Journal:  Diagn Microbiol Infect Dis       Date:  1998-04       Impact factor: 2.803

2.  Efficacy of LY303366 against amphotericin B-susceptible and -resistant Aspergillus fumigatus in a murine model of invasive aspergillosis.

Authors:  P E Verweij; K L Oakley; J Morrissey; G Morrissey; D W Denning
Journal:  Antimicrob Agents Chemother       Date:  1998-04       Impact factor: 5.191

3.  In vitro activity of a new echinocandin, LY303366, compared with those of amphotericin B and fluconazole against clinical yeast isolates.

Authors:  O Uzun; S Kocagöz; Y Cetinkaya; S Arikan; S Unal
Journal:  Antimicrob Agents Chemother       Date:  1997-05       Impact factor: 5.191

4.  Comparison of the in vitro activities of the echinocandin LY303366, the pneumocandin MK-0991, and fluconazole against Candida species and Cryptococcus neoformans.

Authors:  T V Krishnarao; J N Galgiani
Journal:  Antimicrob Agents Chemother       Date:  1997-09       Impact factor: 5.191

5.  Comparison of In vitro activities of the new triazole SCH56592 and the echinocandins MK-0991 (L-743,872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts.

Authors:  A Espinel-Ingroff
Journal:  J Clin Microbiol       Date:  1998-10       Impact factor: 5.948

6.  Quality control limits for broth microdilution susceptibility tests of ten antifungal agents.

Authors:  A L Barry; M A Pfaller; S D Brown; A Espinel-Ingroff; M A Ghannoum; C Knapp; R P Rennie; J H Rex; M G Rinaldi
Journal:  J Clin Microbiol       Date:  2000-09       Impact factor: 5.948

7.  Antifungal activity of LY303366, a novel echinocandin B, in experimental disseminated candidiasis in rabbits.

Authors:  R Petraitiene; V Petraitis; A H Groll; M Candelario; T Sein; A Bell; C A Lyman; C L McMillian; J Bacher; T J Walsh
Journal:  Antimicrob Agents Chemother       Date:  1999-09       Impact factor: 5.191

8.  In vitro activity of a new semisynthetic echinocandin, LY-303366, against systemic isolates of Candida species, Cryptococcus neoformans, Blastomyces dermatitidis, and Aspergillus species.

Authors:  G G Zhanel; J A Karlowsky; G A Harding; T V Balko; S A Zelenitsky; M Friesen; A Kabani; M Turik; D J Hoban
Journal:  Antimicrob Agents Chemother       Date:  1997-04       Impact factor: 5.191

9.  Antifungal efficacy, safety, and single-dose pharmacokinetics of LY303366, a novel echinocandin B, in experimental pulmonary aspergillosis in persistently neutropenic rabbits.

Authors:  V Petraitis; R Petraitiene; A H Groll; A Bell; D P Callender; T Sein; R L Schaufele; C L McMillian; J Bacher; T J Walsh
Journal:  Antimicrob Agents Chemother       Date:  1998-11       Impact factor: 5.191

10.  In vitro activity of the echinocandin antifungal agent LY303,366 in comparison with itraconazole and amphotericin B against Aspergillus spp.

Authors:  K L Oakley; C B Moore; D W Denning
Journal:  Antimicrob Agents Chemother       Date:  1998-10       Impact factor: 5.191
View more
  23 in total

1.  Potency of anidulafungin compared to nine other antifungal agents tested against Candida spp., Cryptococcus spp., and Aspergillus spp.: results from the global SENTRY Antimicrobial Surveillance Program (2008).

Authors:  Shawn A Messer; Ronald N Jones; Gary J Moet; Jeffrey T Kirby; Mariana Castanheira
Journal:  J Clin Microbiol       Date:  2010-06-09       Impact factor: 5.948

Review 2.  Rare and emerging opportunistic fungal pathogens: concern for resistance beyond Candida albicans and Aspergillus fumigatus.

Authors:  M A Pfaller; D J Diekema
Journal:  J Clin Microbiol       Date:  2004-10       Impact factor: 5.948

3.  Antifungal susceptibility patterns of opportunistic fungi in the genera Verruconis and Ochroconis.

Authors:  S Seyedmousavi; K Samerpitak; A J M M Rijs; W J G Melchers; J W Mouton; P E Verweij; G S de Hoog
Journal:  Antimicrob Agents Chemother       Date:  2014-03-31       Impact factor: 5.191

4.  Caspofungin susceptibility in Aspergillus and non-Aspergillus molds: inhibition of glucan synthase and reduction of beta-D-1,3 glucan levels in culture.

Authors:  Jennifer Nielsen Kahn; Ming-Jo Hsu; Fred Racine; Robert Giacobbe; Mary Motyl
Journal:  Antimicrob Agents Chemother       Date:  2006-06       Impact factor: 5.191

5.  Madurella mycetomatis is not susceptible to the echinocandin class of antifungal agents.

Authors:  Wendy W J van de Sande; Ahmed H Fahal; Irma A J M Bakker-Woudenberg; Alex van Belkum
Journal:  Antimicrob Agents Chemother       Date:  2010-03-29       Impact factor: 5.191

6.  Use of amplified fragment length polymorphism to identify 42 Cladophialophora strains related to cerebral phaeohyphomycosis with in vitro antifungal susceptibility.

Authors:  Hamid Badali; G Sybren de Hoog; Ilse Curfs-Breuker; Corné H W Klaassen; Jacques F Meis
Journal:  J Clin Microbiol       Date:  2010-04-26       Impact factor: 5.948

7.  Susceptibility profile of echinocandins, azoles and amphotericin B against yeast phase of Talaromyces marneffei isolated from HIV-infected patients in Guangdong, China.

Authors:  H-L Lei; L-H Li; W-S Chen; W-N Song; Y He; F-Y Hu; X-J Chen; W-P Cai; X-P Tang
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2018-03-13       Impact factor: 3.267

Review 8.  Infections caused by Scedosporium spp.

Authors:  Karoll J Cortez; Emmanuel Roilides; Flavio Quiroz-Telles; Joseph Meletiadis; Charalampos Antachopoulos; Tena Knudsen; Wendy Buchanan; Jeffrey Milanovich; Deanna A Sutton; Annette Fothergill; Michael G Rinaldi; Yvonne R Shea; Theoklis Zaoutis; Shyam Kottilil; Thomas J Walsh
Journal:  Clin Microbiol Rev       Date:  2008-01       Impact factor: 26.132

9.  Activity of contemporary antifungal agents, including the novel echinocandin anidulafungin, tested against Candida spp., Cryptococcus spp., and Aspergillus spp.: report from the SENTRY Antimicrobial Surveillance Program (2006 to 2007).

Authors:  Shawn A Messer; Gary J Moet; Jeffrey T Kirby; Ronald N Jones
Journal:  J Clin Microbiol       Date:  2009-04-22       Impact factor: 5.948

10.  Hospital-acquired phaeohyphomycosis due to Exserohilum rostratum in a child with leukemia.

Authors:  Maude Saint-Jean; Guy St-Germain; Céline Laferrière; Bruce Tapiero
Journal:  Can J Infect Dis Med Microbiol       Date:  2007-05       Impact factor: 2.471
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.